Cell And Gene Therapy Market, by Therapy Type (Cell Therapy and Gene Therapy), by Indication (Cardiovascular Disease, Cancer, Genetic Disorders, Infectious Diseases, Neurological Disorders), by Scale of Operation (In-house and Outsourced), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 15,580.3 Million in 2022 and is projected to exhibit a CAGR of 24.7% over the forecast period (2022– 2030).

Increasing collaboration agreements between key market players is expected to drive growth of the global cell and gene therapy market over the forecast period. For instance on January 6, 2022, Amgen, a U.S. based multinational biopharmaceutical company and Generate Biomedicines, a therapeutics company, announced a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities. As part of the research agreement collaboration, Amgen would pay US$50 million in upfront funding for the initial five programs with a potential transaction value of US$1.9 billion plus future royalties. For each program, Amgen would pay up to US$370 million in future milestones.

Increasing acquisitions by market players boosts growth of the global cell and gene therapy market over the forecast period. For instance, in March, 2021, Amgen Inc., a U.S. based multinational biopharmaceutical company and Rodeo Therapeutics Corporation, a biotechnology company, announced an agreement under which Amgen would acquire Rodeo, which develops small-molecule therapies designed to promote regeneration and repair of multiple tissues. The agreement would help in company in expansion to develop therapeutics for patients using Rodeo's 15-PGDH (a prostaglandin-degrading enzyme) program with Amgen's inflammation portfolio.

Global Cell and Gene Therapy Market– Impact of Coronavirus (COVID-19) Pandemic

The coronavirus or COVID-19 outbreak started in Wuhan, China in 2019 and has spread across all the continents of the world, affecting various industries globally. The economy in countries all over the world such as India, Italy, Bangladesh, Sri Lanka, the U.S., Morocco, and others has been disrupted due to lockdowns implemented by governments to combat the spread of coronavirus since 2020.

Decrease in collection and donation of stem cell during the covid-19 pandemic has hindered growth of the global cell and gene therapy market. For instance, on November 2021, according to the reports published in Bone Marrow Transplantation, an online scientific journal, published a report on Stem cell donor registry activities during the COVID-19 pandemic: a field report by DKMS ('Deutsche Knochenmarkspenderdatei') life science lab, a genotyping service providing company, which reported that during the COVID-19 pandemic, stem cell collections (peripheral blood stem cells and bone marrow) donors decreased by 15.9% worldwide from 156.2/week to 131.3/week ,Corresponding values for DKMS ('Deutsche Knochenmarkspenderdatei') Germany donors were 113.2/week and 97.5/week indicating a 13.8% decrease.

Thus, impact of the Coronavirus (COVID-19) pandemic had hindered growth of the global cell and gene therapy market.          

Global Cell and Gene Therapy Market: Key Developments

Increasing organic strategies by key market players drives growth of the global cell and gene therapy market over the forecast period. For instance, on March 2021, Biogen, a U.S. based multinational biotechnology company, had planned for a new gene therapy manufacturing facility at its Research Triangle Park campus in North Carolina, southeastern region of the U.S. The 175,000-square-foot facility had been designed to scale up the manufacturing of the products that are in Biogen's gene therapy pipeline i.e. BIIB111 (timrepigene emparvovec) to treat the inherited retinal disease choroideremia. The expansionin will help Biogen in development of new revenue source.

Moreover on May, 2021, Biogen Inc, a U.S. based multinational biotechnology company, announced topline results from the Phase 2/3 XIRIUS study of cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients with X-linked retinitis pigmentosa (XLRP). XLRP is a rare, inherited retinal disease that is associated with progressive vision loss as the light-sensing cells of the retina gradually deteriorate. Initial symptoms are difficulty seeing at night, followed by restriction of the field of vision and eventually blindness in most people by the age of 40. Patients living with X-linked retinitis pigmentosa (XLRP) currently have no approved treatments.

Browse 35 Market Data Tables and 28 Figures spread through 164 Pages and in-depth TOC on Cell and Gene Therapy Market, by Therapy Type (Cell Therapy and Gene Therapy), by Indication (Cardiovascular Disease, Cancer, Genetic Disorders, Infectious Diseases, Neurological Disorders), by Scale of Operation (In-house and Outsourced), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2030”

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/cell-and-gene-therapy-market-2475

Key Takeaways of the Global Cell and Gene Therapy Market:

  • Global cell and gene therapy market is expected to witness a CAGR of 24.7 % during the forecast period, owing to increasing prevalence of cardiovascular diseases, cancer, and neurological disorders.
  • Among therapy type, the gene therapy segment held a dominant position in the cell and gene therapy market in 2022. For instance, in November 2018, Pharma Intelligence UK Limited, a pharmaceutical, medtech and clinical research company, estimated that around 55% of the pipeline is of gene therapy, majorly medicines that are delivered by in vivo.
  • Among indication, cancer segment held a dominant position in the cell and gene therapy market in 2022, as majority of cell and gene therapies consist of cancer medicines in development stage
  • Key players operating in the global cell and gene therapy market include, Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis, Pfizer, Regeneron Pharmaceuticals and Sanofi, Spark Therapeutics, Agilis Biotherapeutics, Angionetics AVROBIO, Freeline Therapeutics, Horama, MeiraGTx, Myonexus Therapeutics, Nightstar Therapeutics, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., MEDIPOST, and Bluebird Bio. Inc.

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo